Zn^(2+)和TiO_(2)合金化过程中不同成分占比对薄膜结构和光催化性能的影响

使用溶胶-凝胶法在单晶硅衬底上制备一批不同Zn^(2+)成分调节的TiO_(2)薄膜,观测Zn^(2+)和TiO_(2)合金化过程中光学和光催化性能的变化.X射线衍射光谱仪用于观测在合金化过程中薄膜的晶体结构变化并追踪ZnTiO_(3)化合物的形成.扫描电子显微镜、原子力显微镜用于观测合金化过程中因TiO_(2)晶格对Zn^(2+)溶解度有限而导致薄膜表面出现大量孔洞的现象.X射线光电子能谱和光学带隙用于观测Zn^(2+)与TiO_(2)合金化过程中电子结构层面的变化.最后,通过降解亚甲基蓝(MB)溶液,表明少量Zn^(2+)掺杂完全溶解在TiO_(2)中,并破坏TiO_(2)结晶质量.在Zn^(2+)的成分占比继续提高至15%的过程中,XPS峰形拟合结果验证了TiO_(2)对Zn^(2+)的溶解度有限,导致薄膜出现大量孔洞结构,薄膜的活性比表面积得以提升,同时Zn^(2+)可以有效地捕获光生e^(-)/h^(+).为了继续观察Zn^(2+)浓度对TiO_(2)的影响,将Zn^(2+)的浓度提升至40%,观察Zn^(2+)与TiO_(2)合金化过程中的现象.表明化合物ZnTiO_(3)的出现可以充当e^(-)/h^(+)的复合中心以及TiO_(2).占比的大幅下降导致合金化之后的薄膜光催化效率逐渐下降.

Plasma-assisted aerogel interface engineering enables uniform Zn^(2+)flux and fast desolvation kinetics toward zinc metal batteries

The poor reversibility of Zn anodes induced by dendrite growth,surface passivation,and corrosion,severely hinders the practical applicability of Zn metal batteries.To address these issues,a plasmaassisted aerogel(PAG)interface engineering was proposed as efficient ion transport modulator that can simultaneously regulate uniform Zn^(2+)flux and desolvation behavior during battery operation.The PAG with ordered mesopores acted as an ion sieve to homogenize Zn deposition and accelerate Zn^(2+)flux,which is favorable for corrosion resistance and dendrite suppression.Importantly,the plasma-assisted aerogel with abundant hydrophilic groups can facilitate the desolvation kinetics of Zn^(2+)due to the multiple hydrogen-bonding interaction with the activated water molecules,thus accelerating the Zn^(2+)migration kinetics.Consequently,the Zn/Zn cell assembled with PAG-modified separator demonstrates stable plating and stripping behavior(over 1400 h at 1 mA cm^(-2))and high Coulombic efficiency(99.8%at1 mA cm^(-2)after 1100 cycles),and the Zn‖MnO_(2)full cell shows excellent long-term cycling stability and maintains a high capacity of 154.9 mA h g^(-1)after 1000 cycles at 1 A g^(-1).This study provides a feasible approach for the large-scale fabrication of aerogel functionalized separators to realize ultra-stable Zn metal batteries.

基于不同荧光发色基团的Zn^(2+)荧光探针的研究进展

荧光光谱法具有灵敏度高、选择性好、检出限低以及操作简单等特点,设计合成特异性识别和检测Zn^(2+)的荧光探针对化学、生物学、临床医学等研究具有十分重要的意义。以近年来文献报道的Zn^(2+)荧光探针为例,综述了基于不同荧光发色基团的Zn^(2+)荧光探针的作用机制、应用与发展前景,为Zn^(2+)荧光探针研究提供了参考(引用文献44篇)。

Delayed treatment of diabetic foot ulcer in patients with type 2 diabetes and its prediction model

BACKGROUND Diabetic foot(DF)is a serious complication of type 2 diabetes.This study aimed to investigate the factors associated with DF occurrence and the role of delayed medical care in a cohort of patients with type 2 diabetes.AIM To reveal the impact of delayed medical treatment on the development of DF in patients with type 2 diabetes and to establish a predictive model for DF.METHODS In this retrospective cohort study,292 patients with type 2 diabetes who underwent examination at our hospital from January 2023 to December 2023 were selected and divided into the DF group(n=82,DF)and nondiabetic foot group(n=210,NDF).Differential and correlation analyses of demographic indicators,laboratory parameters,and delayed medical treatment were conducted for the two groups.Logistic regression was applied to determine influencing factors.Receiver operating characteristic(ROC)analysis was performed,and indicators with good predictive value were selected to establish a combined predictive model.RESULTS The DF group had significantly higher body mass index(BMI)(P<0.001),disease duration(P=0.012),plasma glucose levels(P<0.001),and HbA1c(P<0.001)than the NDF group.The NDF group had significantly higher Acute Thrombosis and Myocardial Infarction Health Service System(ATMHSS)scores(P<0.001)and a significantly lower delayed medical treatment rate(72.38%vs 13.41%,P<0.001).BMI,duration of diabetes,plasma glucose levels,HbA1c,diabetic peripheral neuropathy,and nephropathy were all positively correlated with DF occurrence.ATMHSS scores were negatively correlated with delayed time to seek medical treatment.The logistic regression model revealed that BMI,duration of diabetes,plasma glucose levels,HbA1c,presence of diabetic peripheral neuropathy and nephropathy,ATMHSS scores,and delayed time to seek medical treatment were influencing factors for DF.ROC analysis indicated that plasma glucose levels,HbA1c,and delayed medical treatment had good predictive value with an area under the curve of 0.933 for the combined predictive model.CONCLUSION Delayed medical treatment significantly affects the probability of DF occurrence in patients with diabetes.Plasma glucose levels,HbA1c levels,and the combined predictive model of delayed medical treatment demonstrate good predictive value.

Are treatment options used for adult-onset type 2 diabetes mellitus(equally)available and effective for children and adolescents?

Youth-onset type 2 diabetes mellitus(T2DM),influenced by an increase in obesity,is a rising problem worldwide.Pathophysiological mechanisms of this early-onset T2DM include both peripheral and hepatic insulin resistance,along with increa-sed hepatic fasting glucose production accompanied by inadequate first and second-phase insulin secretion.Moreover,the incretin effect is reduced.The initial presentation of type 2 diabetes can be dramatic and symptoms may overlap with those of type 1 diabetes mellitus.Therefore,immediate therapy should address hyperglycemia and associated metabolic derangements irrespective of ultimate diabetes type,while further therapy adjustments are prone to patients’pheno-type.New agents with proven glycemic and beyond glycemia benefits,such as Glucagon-like polypeptide 1 receptor agonists and Sodium-glucose cotransporter-2 inhibitors,used in the adult population of T2DM patients,might become increasingly important in the treatment armamentarium.Moreover,metabolic surgery is an option for markedly obese(body mass index>35 kg/m^(2))children and adolescents suffering from T2DM who have uncontrolled glycemia and/or serious comorbidities when lifestyle and pharmacologic interventions fail.In this mini-review,we will discuss the potential of treatment options considering new data available from randomized control trials,including individuals with adult-onset type diabetes mellitus.

Clinical Observation of Serum Anti-PLA2R Antibody Levels in the Treatment of Idiopathic Membranous Nephropathy with Rituximab

Objective:To investigate the efficacy of rituximab in the treatment of idiopathic membranous nephropathy with varying levels of serum phospholipase A2 receptor antibodies.Methods:A total of 137 patients with idiopathic membranous nephropathy admitted to Beijing Sixth Hospital were selected.Based on their blood PLA2R antibody levels before rituximab treatment,patients were categorized into the PLA2R antibody positive group(n=94)and the PLA2R antibody negative group(n=43).They were followed up for at least 1 year,during which the efficacy,measured through 24-hour urine protein quantification and serum albumin levels,were compared between the two groups before and after treatment.Results:After 3 months of treatment,there was no significant difference in the quantitative levels of 24-hour urine protein between the two groups(P>0.05).However,after 6 and 12 months of treatment,there was a significant difference in the levels of 24-hour urine protein between the two groups(P<0.05).Additionally,after 3 months of treatment,there was a notable difference in the serum albumin levels between the two groups(P<0.05).However,after 6 and 12 months of treatment,there was no significant difference in serum albumin levels between the two groups(P>0.05).Analysis of complications in the two groups revealed that in the positive group,9 individuals experienced thrombosis,5 had infections,and 11 developed acute kidney injury(AKI).In contrast,in the negative group,5 individuals had thrombosis,2 had infections,and 3 developed AKI.There was no statistically significant difference in complications between the two groups(P>0.05).Conclusion:Serum anti-PLA2R antibody levels provide valuable insights into the clinical observation of rituximab treatment for idiopathic membranous nephropathy.They aid in understanding the disease’s pathogenesis,evaluating treatment efficacy,and predicting disease prognosis.

Zn^(2+)/Zn和Fe^(3+)/Fe^(2+)的电化学行为及其在液流电池中的应用

锌铁液流电池采用成本低廉的锌、铁元素作为活性物质,有望成为下一代高性价比储能电池。本文利用循环伏安法测试锌、铁离子在碳毡电极表面的电化学活性,计算Zn^(2+)/Zn与Fe^(3+)/Fe^(2+)的扩散系数与反应速率常数。结果表明,锌离子与铁离子在多孔碳毡上具有良好的电化学性能,可以作为锌铁液流电池的活性物质。充放电测试结果表明,锌铁液流电池的充放电性能良好,它具有较高的电流效率、电压效率和能量效率。

结核特异性IL-2释放试验在结核感染中的诊断价值探讨

目的基于结核特异性白细胞介素2(IL-2)释放试验的结果,探讨IL-2在辅助诊断活动性结核(ATB)感染中的作用,以及用于监测治疗效果的价值。方法回顾性分析临床进行了结核感染排查的病例599例,其中确诊为活动性结核感染的病例128例,除外活动性结核感染的病例471例。(1)对与阴性对照共同孵育后上清中IL-2(N)检测值制作ROC工作曲线,分析失去抗原刺激后PBMCs持续释放IL-2的能力;(2)对抗原刺激后的响应值IL-2(T-N),制作ROC工作曲线,分析对活动性结核感染的诊断价值;(3)对比分析两组患者IL-2的阳性率;(4)观察响应值IL-2(T-N)阴性和阳性转化时间与疾病进程的依从性。结果IL-2(N)ROC曲线下面积为0.460,95%CI 0.402~0.516;IL-2(T-N)ROC曲线下面积为0.788,95%CI 0.745~0.832;在活动性结核感染组,IL-2(T-N)的阳性率显著高于非活动性结核感染组(χ^(2)=110.858,P<0.001);IL-2发生阴阳性转化的平均时间为3.1个月,时间区间为0.5~7个月。结论PBMCs失去抗原刺激后IL-2仅低水平分泌,对诊断ATB没有价值;结核分枝杆菌特异性抗原刺激后的响应值IL-2(T-N),用于诊断ATB具有一定准确性;IL-2(T-N)阴阳性转化的时间较短,在监测治疗效果方面存在一定价值,监测时间间隔建议为3个月。

连续识别Zn^(2+)和草甘膦荧光探针的合成与应用

以2-巯基苯并噻唑为原料,设计合成了一种结构简单的苯并噻唑类荧光探针2-[2-(苯并噻吩-2-基亚甲基)肼基]苯并噻唑(简称NSS),并通过FTIR、HRMS、^(1)HNMR、^(13)CNMR对其结构进行了表征。荧光光谱表明,在二甲基亚砜中,探针NSS实现了Zn^(2+)的“关-开”型检测,具有响应时间短(30 s)、特异性强、抗干扰性强等优点。探针NSS荧光强度与Zn^(2+)浓度(0~11μmol/L)呈现良好的线性关系,检出限达19.1 nmol/L,并与Zn^(2+)形成物质的量比为1∶1的络合物。同时,络合物NSS-Zn^(2+)对草甘膦呈现特异性的荧光猝灭响应,猝灭率达99.4%,检出限16.0 nmol/L(2.71 ng/mL),且不受其他有机磷农药的干扰。

CO_(2)预处理对CR-39中子个人剂量计增敏特性的研究

本文研究了CO_(2)预处理对CR-39探测器灵敏度及径迹特征形成影响。以经^(252)Cf中子源照射的CR-39探测器为研究对象,通过统计探测器记录径迹数与径迹尺寸,分析了不同CO_(2)预处理时间和压力对CR-39探测器灵敏度及径迹尺寸分布的影响规律。研究结果表明:经CO_(2)预处理后CR-39探测器灵敏度及最大径迹尺寸得到显著提高,灵敏度最大提升870%,最大径迹尺寸由20μm增大至40μm;探测器灵敏度与预处理压力时间存在特定正相关关系,灵敏度随CO_(2)压力线性增大;最大径迹尺寸在40μm附近增长达到饱和,继续提高预处理时间和压力,径迹包含的中子能谱特征不再被保留;本实验获得的CO_(2)预处理下CR-39形成径迹保留能谱特征的最佳灵敏度为6.25 tracks·mm^(-2)·mSv^(-1)。这项研究对于提高CR-39中子个人剂量计灵敏度及选择合适CO_(2)预处理条件方面具有重要意义,同时也提供了一种在提升径迹可读性时保留径迹能谱特征信息的预处理方法,可应用于基于中子能谱特征优化中子个人剂量当量评估。

基于“脾主运化,在体合肌”理论探析T2DM肌少症骨骼肌细胞铁死亡发病机制及辨证论治

2型糖尿病(Type 2 diabetes mellitus,T2DM)伴随的衰老性疾病是目前糖尿病领域研究热点,肌少症现已成为T2DM继微血管和大血管病变之外的第三大类并发症,能够导致骨折、失能、活动障碍等多种不良事件的发生发展。脾属土,居中焦,主运化,在体合肌。脾之健运、精气得布、肌肉充养,方可发挥正常生理功能。近年研究表明,骨骼肌细胞铁死亡在T2DM肌少症发病机制中具有重要作用。基于“脾主运化,在体合肌”理论,从中医学“脾失运化、精气亏虚、湿浊困阻、肌肉失养”病机观及现代医学“骨骼肌细胞铁死亡”病理机制的角度对T2DM肌少症发病机制进行探讨,归纳T2DM肌少症从脾论治的中医防治原则,为丰富脾藏象理论内涵以及中医药防治T2DM肌少症基础研究和临床试验提供理论支撑。

2型糖尿病中西医结合诊疗指南

2型糖尿病(T2DM)是全球性的公共卫生问题,目前我国患病总人数已超过1亿。为指导2型糖尿病规范化中西医诊疗,中国中西医结合学会联合中华中医药学会、中华医学会共同开展中西医结合诊疗方案制订工作,本指南组织国内22位内分泌及相关领域中西医专家,通过前期调研、专家访谈、共识会议,结合循证医学证据,最终形成了2型糖尿病中西医结合诊疗指南。主要内容包括2型糖尿病的诊断标准、高危人群筛查、中医证候分型、治疗原则和方法。治疗方案涵盖健康教育与管理、营养与药膳、运动与功法、心理调节与情志疗法,以及中药辨证论治、中成药、中医外治法等中医疗法与西药的联合干预。强调以患者为中心,注重个体化治疗,旨在改善血糖控制,减少并发症,提高生活质量。本指南适用于中医、中西医结合医疗机构的临床医师及相关护理人员,也可供西医临床医师和健康管理相关专业人员参考。

德曲妥珠单抗对比化疗方案二线治疗HER-2低表达晚期乳腺癌的经济学评价

目的 从我国卫生体系角度出发,评价德曲妥珠单抗方案对比医生选择化疗(TPC)方案二线治疗人表皮生长因子受体2(HER-2)低表达晚期乳腺癌的经济性。方法 基于DESTINY-Breast04临床试验数据构建动态Markov模型,模拟时限为10年,循环周期为3周。以成本、质量调整生命年(QALY)、增量成本-效果比(ICER)作为模型产出指标,采用5%的贴现率,以3倍2023年我国人均国内生产总值(GDP)作为意愿支付(WTP)阈值,采用成本-效用分析法分析激素受体阳性队列和所有患者队列中两种治疗方案的经济性,再通过不确定性分析验证基础分析结果的稳健性。结果 基础分析结果显示,德曲妥珠单抗方案与TPC方案相比,在激素受体阳性队列和所有患者队列中的ICER值分别为1 045 655.76、906 404.99元/QALY,均高于WTP阈值(268 074元/QALY)。单因素敏感性分析结果显示,疾病无进展状态效用值、德曲妥珠单抗价格、疾病进展状态效用值等参数对模型结果影响较大。概率敏感性分析结果显示,当WTP阈值为3倍2023年我国人均GDP时,德曲妥珠单抗方案具有经济性的概率为0。情境分析结果显示,在考虑援助计划时,德曲妥珠单抗方案具有经济性的概率为0;当德曲妥珠单抗价格降低70%时,该方案具有经济性的概率显著提高至82.80%。结论 在以3倍2023年我国人均GDP作为WTP阈值时,德曲妥珠单抗方案相对于TPC方案二线治疗HER-2低表达晚期乳腺癌不具有经济性;按地区适当降低德曲妥珠单抗的价格,可以提高其经济性。

血清IL-2、sST2表达与特发性膜性肾病免疫抑制剂治疗反应性的相关性

目的探讨特发性膜性肾病患者血清白介素-2(IL-2)、可溶性生长刺激表达基因2蛋白(sST2)表达水平与免疫抑制剂治疗反应性的相关性。方法选取2020年1月至2022年10月于医院接受免疫抑制剂治疗的135例特发性膜性肾病患者,于入院时检测患者血清IL-2、sST2,并于治疗完成后测定24 h尿蛋白定量,依据患者治疗反应性分为缓解组与未缓解组。对比两组患者一般资料及入院时血清IL-2、sST2水平,采用点二列相关性分析血清IL-2、sST2水平与特发性膜性肾病免疫抑制剂治疗反应性的关系,并绘制受试者工作特征(ROC)曲线评估血清IL-2、sST2水平预测特发性膜性肾病免疫抑制剂治疗反应性的价值。结果135例特发性膜性肾病患者中共有132例完成规律治疗,经免疫抑制剂治疗6个月后,101例患者疾病缓解,纳入缓解组,其余31例患者纳入未缓解组。未缓解组年龄、入院时肾功能分级、疾病分期、血清IL-2、sST2水平均高于缓解组,差异有统计学意义(P<0.05);点二列相关性分析显示,血清IL-2、sST2水平与特发性膜性肾病免疫抑制剂治疗反应性不良风险呈正相关(r 1=0.428,P 1<0.001;r 2=0.344,P 2<0.001);绘制ROC曲线,结果显示,血清IL-2、sST2预测特发性膜性肾病免疫抑制剂治疗反应性不良的曲线下面积均>0.7,具有一定预测价值,且联合预测价值更高。结论血清IL-2、sST2表达水平与特发性膜性肾病患者免疫抑制剂治疗反应性密切相关,二者表达水平越高,治疗反应性越差,且联合检测可作为预测特发性膜性肾病患者免疫抑制剂治疗反应性的敏感指标。

Zn^(2+)与腐殖酸钠组合抑制剂对萤石、方解石浮选分离的影响及机理研究

常见的方解石型萤石矿由于方解石与萤石表面物理化学性质相似,两者的浮选分离较为困难。本文研究了ZnSO_(4)·7H_(2)O与腐殖酸钠组合抑制剂对萤石和方解石选择性分离浮选的影响,通过吸附量测定、XPS检测、红外光谱分析以及溶液化学计算进行了机理分析。实验结果表明,相比于单一腐殖酸钠抑制剂,当使用腐殖酸钠与ZnSO_(4)·7H_(2)O质量比为3∶1的组合抑制剂且其用量为20 mg/L、油酸钠用量为1.5×10^(-4)mol/L、pH为7的条件下,可使萤石、方解石浮选回收率之差由41.8百分点提高到70.31百分点。腐殖酸钠与Zn^(2+)发生化学反应生成的腐殖酸锌与单一抑制剂相较方解石表面腐殖酸根吸附量有所提高;而萤石表面腐殖酸根吸附量减少,更多活性位点与油酸钠结合,油酸钠的吸附量提高,进而提高了组合抑制剂在两种矿物表面的选择性吸附,最终达到浮选分离的目的。

长效胰岛素联合口服降糖药治疗2型糖尿病的疗效

目的 分析2型糖尿病(T2DM)采取长效胰岛素+口服降糖药治疗的效果。方法 96例T2DM患者,随机分为观察组和对照组,每组48例。对照组给予口服降糖药治疗,观察组给予长效胰岛素+口服降糖药治疗。比较两组患者治疗前后的血糖[糖化血红蛋白(HbA1c)、餐后2 h血糖(2 h PG)、空腹血糖(FPG)]水平、生活质量(总体健康、精力、社会功能、心理健康、躯体疼痛、躯体角色功能、情绪角色功能、躯体健康)评分以及不良反应发生情况(体重增加、低血糖)、治疗效果。结果 治疗后,观察组患者HbA1c(6.20±0.91)%、2 h PG(8.63±1.37)mmol/L、FPG(5.83±0.72)mmol/L均低于对照组的(8.34±1.15)%、(9.56±1.60)mmol/L、(7.91±1.31)mmol/L,差异具有统计学意义(P<0.05)。观察组不良反应发生率2.08%(1/48)低于对照组的14.58%(7/48),差异具有统计学意义(χ^(2)=4.909,P<0.05)。治疗后,观察组患者总体健康评分(63.25±4.48)分、精力评分(74.25±4.54)分、社会功能评分(83.67±3.91)分、心理健康评分(81.48±4.25)分、躯体疼痛评分(74.48±6.38)分、躯体角色功能评分(73.54±4.18)分、情绪角色功能评分(84.54±3.67)分、躯体健康评分(71.37±4.28)分;对照组患者总体健康评分(54.54±3.25)分、精力评分(61.22±4.01)分、社会功能评分(76.32±2.75)分、心理健康评分(61.24±3.75)分、躯体疼痛评分(66.58±4.70)分、躯体角色功能评分(61.24±4.42)分、情绪角色功能评分(73.05±2.50)分、躯体健康评分(52.31±2.76)分。观察组患者总体健康、精力、社会功能、心理健康、躯体疼痛、躯体角色功能、情绪角色功能、躯体健康评分均高于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率95.83%高于对照组的79.17%,差异具有统计学意义(P<0.05)。结论 长效胰岛素联合口服降糖药物对T2DM治疗可有效改善血糖水平,降低不良反应发生率,提升疗效。

德谷胰岛素联合西格列汀二甲双胍治疗难治性2型糖尿病的临床研究

目的探讨德谷胰岛素联合西格列汀二甲双胍治疗难治性2型糖尿病患者的临床效果。方法选取2021年5月至2023年3月我院收治的84例难治性2型糖尿病住院患者,随机分为试验组(42例)和参照组(42例)。参照组采用西格列汀二甲双胍治疗,试验组采用德谷胰岛素联合西格列汀二甲双胍治疗。比较两组的血糖水平、低血糖发生情况。结果治疗12周后,两组空腹血糖(FPG)、餐后2h血糖(2hPBG)和糖化血红蛋白(HbA1c)水平降低,且试验组FPG、2hPBG、HbA1c水平低于参照组(P<0.05)。试验组治疗期间低血糖发生率为11.90%,与参照组的9.52%无统计学差异(P>0.05)。结论德谷胰岛素联合西格列汀二甲双胍治疗难治性2型糖尿病患者的控糖效果更佳,且未明显增加低血糖发生风险,安全性较高,值得临床推广。

Zn^(2+)-Ni^(2+)-Al^(3+)-类水滑石@Al薄膜制备及其光催化性能

含过渡金属元素的类水滑石(LDHs)材料在可见光催化领域显示了广泛应用前景.然而LDHs粉末在催化反应中难回收、易流失,不利于材料的循环利用.以铝板为基体,通过原位生长技术在基体表面原位生长Zn^(2+)-Ni^(2+)-Al^(3+)-LDHs,开辟制备Zn^(2+)-Ni^(2+)-Al^(3+)-LDHs@Al材料的新方法.研究表明,Zn^(2+)-Ni^(2+)-Al^(3+)LDHs薄膜在铝基底纵向生长,具有高取向性.LDHs结晶度较高,片层结构规整,极大暴露了LDHs催化活性较高的层板边缘.该薄膜材料具有较低禁带宽度、较高可见光催化活性.Zn^(2+)-Ni^(2+)-Al^(3+)-LDHs@Al能够有效降解甲基橙(MO)有机染料废水,多次循环后对染料的降解率可达98%.该材料极大的增强了对光的利用率,促进了光生电子和空穴对的分离和转移,提高了材料光催化活性,推动和强化了LDHs材料的循环利用及综合处理废水的能力,提高了其应用价值和应用范围,为LDHs材料的开发、设计及应用提供了新思路.

一种基于联萘酚和(R,R)-Salen的高分子荧光探针的合成及对Zn^(2+)的识别研究

利用Sonogashira偶联反应设计合成了一种含有联萘酚和(R,R)-Salen单元的共轭高分子荧光探针P-1,并通过核磁共振氢谱表征了其结构。荧光光谱分析实验结果表明,高分子荧光探针P-1对Zn^(2+)具有高选择性识别,表现出明显的荧光增强,检测限可达到28.11 nmol·L^(-1),因此,高分子荧光探针P-1也具有较高的灵敏度。

Boosting Zn^(2+)kinetics via the multifunctional pre-desolvation interface for dendrite-free Zn anodes

Aqueous zinc ion batteries(AZIBs)are an advanced secondary battery technology to supplement lithiumion batteries.It has been widely concerned and developed recently based on the element abundance and safety advantages.However,AZIBs still suffer from serious problems such as dendrites Zn,hydrogen evolution corrosion,and surface passivation,which hinder the further commercial application of AZIBs.Herein,an in-situ ZnCr_(2)O_(4)(ZCO)interface endows AZIBs with dendrite-free and ultra-low polarization by realizing Zn^(2+)pre-desolvation,constraining H2O-induced corrosio n,and boosting Zn^(2+)transport/deposition kinetics.The ZCO@Zn anode harvests an ultrahigh cumulative capacity of~20000 mA h cm^(-2)(cycle time:over 4000 h)at a high current density of 10 mA cm^(-2),indicating excellent reversibility of Zn deposition,Such superior performance is among the best cyclability in AZIBs.Moreover,the multifunctional ZCO interface improves the Coulombic efficiency(CE)to 99.7%for more than 2600 cycles.The outstanding electrochemical performance is also verified by the long-term cycle stability of ZCO@Zn//α-MnO_(2) full cells.Notably,the as-proposed method is efficient and low-cost enough to enable mass production.This work provides new insights into the uniform Zn electrodeposition at the scale of interfacial Zn^(2+)predesolvation and kinetics improvement.